Which medication is not part of the treatment plan for a client with peptic ulcer disease due to its irritating effects on the gastrointestinal lining?

Ibuprofen is not part of the treatment plan for a client with peptic ulcer disease because it belongs to a class of medications known as nonsteroidal anti-inflammatory drugs (NSAIDs). These drugs can irritate the gastrointestinal (GI) lining and inhibit the production of protective prostaglandins, which are crucial for maintaining the integrity of the mucosal barrier in the stomach and intestines. This mucosal barrier is essential in preventing damage caused by gastric acid, and its compromise can worsen ulcers or lead to new ulcer formation.

In contrast, medications like nizatidine and omeprazole are designed to reduce gastric acid secretion, thereby promoting healing of existing ulcers and preventing further damage. Sucralfate acts by forming a protective barrier over the ulcer, which also helps shield it from acidic gastric contents. Thus, the inclusion of ibuprofen in a treatment plan for peptic ulcer disease can exacerbate symptoms and hinder recovery, making it inappropriate for use in these patients.